Singapore-based startup Lucence recently unveiled LucenceINSIGHT, its pioneering multi-cancer early detection (MCED) blood test, at its US headquarters. The event was attended by Singapore’s Deputy Prime Minister, Coordinating Minister for Economic Policies, and Chairman of the National Research Foundation, Singapore (NRF), Heng Swee Keat.

The startup is launching LucenceINSIGHT, an MCED test, first internationally and with a follow-up US launch in Q3 2023. This ctDNA-based liquid biopsy test screens for 10 common cancers in one blood draw. Globally, 78% of cancer deaths occur in cancers without recommended routine screening. Blood testing will make screening of multiple cancer types more convenient and accessible for asymptomatic individuals.

Lucence was founded in 2016 in Singapore by CEO Dr Min-Han Tan as a spin-off from Singapore’s Agency for Science, Technology and Research (A*STAR) and has since grown into a leading global precision oncology company. With headquarters in Singapore and California, Lucence maintains CLIA-licensed and CAP-accredited laboratories in both locations and operates commercial offices in Hong Kong and Suzhou.